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a b s t r a c t
Background: Recently, mesenteric fat has been proposed to play a role in the pathophysiol-
ogy of Crohn’s disease (CD), as fat hypertrophy is detected close to the affected intestinal 
area; however, there are few studies regarding autophagy and creeping fat tissue in CD. 
Objective: Evaluate autophagy-related proteins and proinflammatory cytokines in intestinal 
mucosa and mesenteric fat in patients with CD and controls. 
Patients and methods: Ten patients with CD, eight with non-inflammatory disease who 
underwent surgery, and eight with normal ileocolonoscopy were studied. The expression 
of LC3-II, TNF-α and IL-23 was determined by immunoblot of protein extracts. In addition, 
total RNA of LC3 and Atg16-L1 were determined using RT-PCR. 
Results: The expression of LC3-II was significantly lower in the mesenteric tissue of CD 
when compared to controls (p < 0.05). In contrast, the intestinal mucosa of the CD group 
had higher levels of LC3-II (p < 0.05). However, mRNA expression of autophagy-related pro-
teins was similar when compared to mesenteric fat groups. TNF-α and IL-23 expressions 
were higher in intestinal mucosa of CD than in control (p < 0.05). 
Conclusion: These findings suggest a defect in the autophagic activity of the creeping fat 
tissue in CD, which could be involved with the maintenance of the inflammatory process 
in the intestinal mucosa. 
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
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r e s u m o
Autofagia e expressão de citocinas pró-inflamatórias na mucosa 
intestinal e no tecido mesenterial de pacientes com doença de Crohn 
Introdução: Recentemente, tem se proposto que o tecido mesenterial possa participar da 
fisiopatologia da DC, uma vez que é notória a hipertrofia da gordura mesenterial próxima 
ao segmento intestinal afetado pela doença. Entretanto, há poucos estudos relacionando 
autofagia e tecido mesenterial na DC. 
Objetivo: Avaliar autofagia e citocinas na mucosa intestinal e no mesentério de pacientes 
com DC. 
Pacientes e métodos: Dez pacientes com DC, oito sem doença inflamatória intestinal que 
foram submetidos à cirurgia, e oito com ileocolonoscopia normal, foram estudados. As ex-
pressões de LC3-II, TNF-α e IL-23 foram determinadas por imunoblot de extrato protéico 
total. Além disso, expressão gênica de LC3 e de Atg16-L1 foi realizada por RT-PCR. 
Resultados: A expressão de LC3-II foi significativamente menor no tecido mesenterial de pa-
cientes com DC quando comparada à dos controles (p < 0,05); as amostras de tecido intes-
tinal do grupo DC apresentaram maior expressão de LC3-II (p < 0,05). Entretanto, as expres-
sões gênicas relacionadas à autofagia foram similares nos grupos de tecido mesenterial. 
Os níveis de TNF-α e de IL-23 foram maiores na mucosa intestinal do grupo CD (p < 0,05). 
Conclusão: Estes achados sugerem alteração da autofagia no mesentério na DC, o que pode 
estar envolvido com a manutenção da inflamação na mucosa intestinal.
Introduction
Autophagy seems to be essential for intestinal mucosal im-
munity, and recent studies show that mutations in autoph-
agy-related genes are associated with CD.1–4 The autophagy 
process has important functions, such as regulation of cell 
survival and cell death. When properly activated, the pro-
cess promotes survival through the degradation of cytoplas-
mic organelles and content via lysosomes, thereby providing 
metabolic fuel for mitochondrial oxidation,5,6 as well as ac-
counting for the removal of proteins generated from cellular 
stress. However, exacerbated autophagy may also lead to cell 
death.7,8 Autophagy can be induced by extracellular and intra-
cellular signals, including oxidative stress, growth factors, ce-
ramide, endoplasmic-reticulum (ER) stress, and glucose and 
amino acid serum starvation.9 
Association of CD with the gene loci ATG16L1 was refer-
eed and patients who had more mutant alleles, develop more 
severe course of disease (stenosis and fistulae), compared to 
those patients with inflammatory CD phenotype only.10
Although there is phenotypic variation in surgical speci-
mens from CD patients, macroscopic aspects are notori-
ous; particularly regarding mesenteric fat thickening near 
the affected intestinal area.11 Mesenteric fat hypertrophy 
and bowel wrapping are characteristic of CD.12 Histological 
analyses revealed abnormalities in adipose tissue, including 
infiltration of macrophages and T cells, perivascular fibrosis 
and inflammation. Moreover, there are increased numbers of 
adipocytes in CD creeping fat, which have been reported to 
be smaller in CD than in controls.13,14 Similar to macrophages 
and epithelial cells, adipocytes from normal individuals are 
able to synthesize several proinflammatory and anti-inflam-
matory cytokines, and fat hormones.15 Indeed, adipocytes 
can express TLR4 for the recognition of local or systemic 
bacterial antigens.16–18 
There have been few reports discussing the role of the 
mesenteric fat tissue in CD.19–24 However, there are no stud-
ies evaluating autophagy in this tissue. Therefore, in order to 
compare the autophagic activity (called ‘macroautophagy’) 
and the expression of proinflammatory cytokines in fat and 
intestinal tissue between CD patients and controls, we used 
immunoblotting to determine LC3, TNF-α, and IL-23 protein 
expression. In addition, we performed RT-PCR assays to de-
termine the relative RNA quantification related to the step of 
membrane elongation and autophagosome formation (LC3II 
and Atg16L1) in mesenteric fat tissue groups.25,26
Patients and methods
Mucosal biopsies were taken from 10 patients with ileocecal 
CD [mean age 34.9 (range, 14–60) years; male 50%; female 
50%]. The presence of disease activity was assessed by colo-
noscopy before surgery, and all patients had Crohn’s disease 
activity index (CDAI)27 over 250 points. The control groups 
were composed of eight patients who underwent retosig-
moidectomy for non-inflammatory disease (megacolon), 
with normal distal ileum (ileum mesenteric fat tissue con-
trol group) [mean age 55.6 (range, 39–70) years; male 62.5%; 
female 37.5%], and eight patients with normal ileocolonos-
copy (intestinal tissue control group) [mean age 50.4 (range, 
33–60) years; male 37.5%; female 62.5%]. 
The study was approved by the local Ethical Committee. 
All biopsies were performed after obtaining informed consent 
from the patients. The study was carried out at the Coloproc-
tology Unit and at the Cell Signaling Laboratory of the Univer-
sidade Estadual de Campinas (UNICAMP).
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
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Mucosal biopsies from the terminal ileum and mesenteric 
fat tissue near the affected intestinal area were snap-frozen 
in liquid nitrogen and stored at −80 °C until ready to be used. 
Western blotting analysis
For total protein extract preparation, the fragments were ho-
mogenized in solubilization buffer at 4  ºC [1% Triton X-100, 
100 mM Tris-HCl (pH 7.4), 100 mM sodium pyrophosphate, 100 
mM sodium fluoride, 10 mM EDTA, 10 mM sodium orthovana-
date, 2.0 mM phenylmethylsulfonyl fluoride (PMSF), and 0.1 mg 
aprotinin/mL] with a Polytron PTA 20S generator (model PT 
10/35; Brinkmann Instruments, Westbury, NY) operated at 
maximum speed for 30 sec. Insoluble material was removed by 
centrifugation (20 min at 110,000 rpm at 4 °C). Protein concen-
tration in the supernatants were determined by the Bradford 
dye binding method.28 Aliquots of the resulting supernatants 
containing 50 μg total proteins were separated by SDS-PAGE, 
transferred to nitrocellulose membranes and blotted with anti-
LC3, anti-TNF-α and anti-IL-23 antibodies.29
Reagents for SDS-PAGE and immunoblotting were from Bio-
Rad Laboratories (Richmond, CA). Phenylmethylsulfonyl fluo-
ride, aprotinin, Triton X-100, Tween 20, and glycerol were from 
Sigma (St. Louis, MO). Nitrocellulose paper (BA85, 0.2 μm) was 
from Amersham (Aylesbury, UK). The anti-LC3 (M115-3, mouse 
monoclonal) antibody was purchased from MBL International 
(MA). The anti-TNF-α (sc-1347, rabbit polyclonal) and anti-IL-23 
(sc-50303, rabbit polyclonal) antibodies were purchased from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Protein molec-
ular weight was assessed by the PageRulerTM from Fermentas 
(Glenburnie, MD). The signal was detected by chemilumines-
cent reaction (SuperSignal®West Pico Chemiluminescent Sub-
strate from Pierce Biothecnology, Inc. Rockford, IL).
All numerical results are expressed as mean ± SEM of the 
indicated number of experiments. Blotting results are pre-
sented as direct comparisons of bands in autoradiographs 
and quantified by densitometry using the Gel-Pro Analyzer 6.0 
software (Exon-Intron Inc., Farrell, MD). Data were analyzed by 
the t-Test, comparing the mesenteric fat tissue of the CD group 
and its respective fat control group; and comparing, separately, 
the intestinal tissue of the CD group and its respective intesti-
nal control group. The level of significance was set at p < 0.05.
RT-PCR analysis
Total RNA was extracted using Trizol (Invitrogen) according to 
the manufacturer instructions. RNA purity and concentration 
were determined by UV spectrophotometry at 260 nm. RNA 
was treated with RNase-free Dnase (RQ1 RNase-free Dnase, 
Promega), then reverse transcribed using oligo (dT) primers 
and reverse transcriptase (RevertAid™ Kit, Fermentas). The 
reaction mixture (20 μl) was incubated at 42  ºC for 60  min, 
then 10 min at 70 ºC, and cooled on ice. RT-PCR was performed 
on resulting cDNA, using the manufacturer protocol, in 25 μL 
reaction volume per capillary. Gene-specific primers (Applied 
Biosystems™) were: Hs00261291 (MAP1LC3-LC3); Hs00250530 
(ATG16-L1); NM_002046.3 (GAPDH). The reaction mixture con-
tained SYBR®Premix Ex Taq™ II (2x), cDNA template, primer 
pair mixture and dH2O. RT-PCR amplification consisted of an 
initial denaturation step (50 ºC for 2 min and 95 ºC for 10 min), 
40 cycles of denaturation (95  ºC for 15  seconds), anneling 
(53  ºC for 20 seconds) and extension (72  ºC for 20 seconds), 
followed by a final incubation at 60 ºC for 1 min. All measure-
ments were normalized by the expression of GAPDH gene, 
considered as a stable housekeeping gene. Gene expression 
was determined using the delta-delta Ct method: 2−▲▲CT
(▲▲CT=[Ct(target gene) – Ct(GAPDH)]patient – [Ct(target gene) – 
Ct(GAPDH)]control)
Real-time PCR analysis of gene expression was performed 
in a 7500 SDS sequence detection system (Applied Biosystems). 
The optimal concentration of cDNA and primers, as well as the 
maximum efficiency of amplification, were obtained through 
five-point, two-fold dilution curve analysis for each gene. Real-
time data were analyzed using the Sequence Detector System 
1.7 (Applied Biosystems). The t-test was used for statistical 
analyses, comparing the mesenteric fat tissue of the CD group 
and its respective fat control group; and comparing, separately, 
the intestinal tissue of CD group and its respective intestinal 
control group. The level of significance was set at p < 0.05.
Results
LC3-II protein expression was significantly lower in the mesen-
teric fat tissue of CD patients (FCD group), when compared to 
controls (FC group) (p < 0.05). Patients with CD also had signifi-
cantly higher levels of LC3-II, TNF-α and IL-23 in intestinal mu-
cosa (ICD group) when compared to intestinal control (IC group) 
(p < 0.05). No difference in cytokine levels was observed among 
the mesenteric groups. Results are showed in Figs. 1 to 6.
Regarding LC3 and ATG16L1 gene expressions, no statisti-
cally significant differences were detected when the mesen-
teric fat tissue groups were compared (p > 0.05). Figs. 7 and 8 
illustrate these findings.
Discussion
Recent genome-wide association studies (GWAS) have in-
creased the number of CD associated susceptibility genes. Two 
of these genes (ATG16L1 and IRGM) modulate autophagy, and 
the variant T300A of ATG16L1 results in a specific defect in 
bacteria-induced autophagy.3,30,31 ATG16L1 and NOD2 risk vari-
ants, in addition to Paneth cell defect, could modify intestinal 
epithelial cell antimicrobial responses.30 However, there is no 
report of autophagy-related protein levels in distinct tissues 
affected by CD, such as intestinal and mesenteric fat tissues.
Autophagy is a cellular process by which a double-mem-
brane structure (autophagosome) surrounds the cytoplasm 
to break captured proteins and cytoplasmic organelles.32 Al-
though Beclin-1 is a part of one of the core Atg (autophagy-
related genes) complexes and participates in the initial au-
tophagy process, in the formation of the isolated membrane, 
LC3-II conjugations are essential for membrane elongation 
and autophagosome formation and are often used as mark-
ers of autophagy. Whereas LC3-I is localized in the cytosol, 
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Fig. 3 – Representative Western blot analyses and 
determination of IL-23 protein expression in the fat tissue of 
control (FC) and Crohn’s disease (FCD) groups. For illustration 
purposes each band represents one patient. For the FCD 
Group, n = 10; for the FC Group, n = 8, *p < 0.05 vs control.
Fig. 1 – Representative Western blot analyses and 
determination of TNF-α protein expression in the fat tissue of 
control (FC) and Crohn’s disease (FCD) groups. For illustration 
purposes each band represents one patient. For the FCD 
Group, n = 10; for the FC Group, n = 8, *p < 0.05 vs control.
Fig. 2 – Representative Western blot analyses and 
determination of TNF-α protein expression in the intestinal 
tissue of control (IC) and Crohn’s disease (ICD) groups. For 
illustration purposes each band represents one patient. For the 
ICD Group, n = 10; for the IC Group, n = 8, *p < 0.05 vs control.
Fig. 4 – Representative Western blot analyses and 
determination of IL-23 protein expression in the intestinal 
tissue of control (IC) and Crohn’s disease (ICD) groups. For 
illustration purposes each band represents one patient. For the 
ICD Group, n = 10; for the IC Group, n = 8, *p < 0.05 vs control.
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LC3-II is localized on the cytoplasmic surface of autophago-
somes and is delipidated by Atg4B to recycle LC3-I for further 
autophagosome formation.33,34 Indeed, Atg16L1 determines 
the site of LC3 conjugation, essential for autophagosome for-
mation, suppressing inflammasome activity and maintaining 
Paneth cells.35,36 Despite great progress since the identification 
of ATG1,37 many questions regarding the molecular regulation 
of autophagy remain unresolved.38
Moreover, autophagy and inflammatory pathways are closely 
linked. Proinflammatory cytokines secretion, such as IL-1β and 
IL-18, were enhanced in ATG16L1 or ATG7 deleted macrophages 
in response to lipopolysaccharide (LPS), displaying increased 
susceptibility to a murine model of colitis.39 Autophagy also sup-
presses endotoxin-induced inflammatory immune responses.40 
Defects of autophagy activity and bacterial receptors (NOD2) 
have been associated with impaired antigen presentation, en-
gaged intracellular removal of pathogenic bacteria and, conse-
quently, higher expression of proinflammatory cytokines.41–45
Autophagy contributes to cellular survival against nutrient 
starvation and the turn-over of injured organelles,46,47 explain-
ing why in the present study was verified high expression of 
autophagy protein in the intestinal tissue of CD patients when 
compared to controls. However, this ability was not verified in 
the hypertrophied mesenteric fat tissue of CD patients, other-
Fig. 6 – Representative Western blot analyses and 
determination of LC3-II protein expression in the intestinal 
tissue of control (IC) and Crohn’s disease (ICD) groups. For 
illustration purposes each band represents one patient. For the 
ICD Group, n = 10; for the IC Group, n = 8, *p < 0.05 vs control.
Fig. 5 – Representative Western blot analyses and 
determination of LC3-II protein expression in the fat tissue of 
control (FC) and Crohn’s disease (FCD) groups. For illustration 
purposes each band represents one patient. For the FCD 









































Fig. 8 – Results of ATG16-L1 gene expression determined by 
RT-PCR. For FCD Group, n = 10; for FC Group, n = 8, *p < 0.05 vs 
control.
Fig. 7 – Results of LC3 gene expression determined by RT-PCR. 
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wise, was found low expression of LC3-II when compared to 
mesenteric tissue of patients without IBD. This LC3-II expres-
sion could lead to an impaired clearance of bacterial species, 
as well as the accumulation of unprocessed unnecessary pro-
teins, which activate proinflammatory pathways involved in CD 
pathogenesis. The higher expression of proinflammatory cyto-
kines in intestinal mucosa, such as TNF-α and IL-23, which sig-
nalize respective Th1 and Th17 lymphocyte response, could also 
explain the higher levels of autophagy protein seen in this study.
Although LC3-II protein expression was lower in the mesen-
teric fat tissue and higher in the intestinal tissue of CD patients, 
no statistical differences were seen among these groups, con-
sidering LC3 and ATG16L1 gene expressions. Reports on the role 
of microRNAs (miRNAs) in autophagy may lead to insights into 
these complex processes. MicroRNAs represent an important 
and still relatively unexplored manner of regulating protein 
synthesis. It does not encode for proteins, but exert catalytic, 
structural or regulatory activities by annealing to specific target 
RNAs, and downregulating their stability and/or translation.48,49 
It has been reported that miRNA-101 is a potent inhibitor of 
autophagy.50 Regarding CD, Brest et al., showed that a family of 
miRNAs, miR-196, is overexpressed in the inflammatory intes-
tinal epithelia of these individuals and there is subsequent loss 
of the tight regulation of IRGM expression, which compromises 
the control of intracellular replication of CD-associated adher-
ent invasive Escherichia coli by autophagy. The association of 
IRGM with CD arises from a miRNA-based alteration in IRGM 
regulation that affects the efficacy of autophagy.51 The results 
of the protein and gene expression in the present study sug-
gest that miRNA alterations could be involved in the complete 
gene transcription, resulting in the defective production of the 
protein. Only one study reporting a miRNA (miR-204) regulat-
ing LC3-II protein has been published, which reported an im-
portant role for this mechanism in myocardial injury;52 how-
ever, there are no studies of miRNA, autophagy regulation, and 
CD in the literature.
Recent studies, in mice, provide insights into how defective 
autophagy in cells, such as macrophages and Paneth cells, may 
contribute to CD,39,53 although none of these studies describe 
these alterations in adipose tissue. It is possible that the defec-
tive autophagy in this tissue could be responsible for maintain-
ing the local production of inflammatory mediators and lead to 
intestinal involvement, especially on mesenteric longitudinal 
side, forming ulcers, characteristic of CD, as described by Crohn 
et al.54 In late stages of the disease, there is a decrease in adipo-
cytes number, as these are substituted by impaired autophagic 
cells of the immune system, such as macrophages,55,56 possible 
explaining why the present study showed a defective autopha-
gy in the mesenteric adipose tissue of CD patients.
The importance in knowing the autophagy pathway in creep-
ing fat tissue in CD can lead us to understand more about the 
phenotype and molecular biology involved in CD and its patho-
genesis, as well as the active role of adipose tissue in the mainte-
nance of the inflammatory process during the course of disease. 
Conclusion
The present study shows a defective expression of protein-
related autophagy in the mesenteric fat tissue of CD patients, 
when compared to controls. Data suggest that the primary 
defects of cell autophagy may not occur at all tissue involved 
by CD, however, it may occur mainly in the adipose tissue, 
close to the affected intestinal area. The mesenteric fat tissue 
could play an important role in the maintenance of local in-
flammation in these patients. Further studies will determine 
whether miRNA has a role in autophagy regulation in patients 
with CD, and whether autophagy can be used for therapeutic 
approaches in the treatment of CD. 
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